Clinical review report Ixekizumab (Taltz) (Eli Lilly Canada Inc.)
The objective of this review is to perform a systematic review of the beneficial and harmful effects of ixekizumab (Taltz) at the recommended dose for the treatment of adult patients with active psoriatic arthritis.
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2018.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820282806719 |
| Sumario: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of ixekizumab (Taltz) at the recommended dose for the treatment of adult patients with active psoriatic arthritis. |
|---|---|
| Descripción Física: | 1 online resource (1 PDF file (111 pages)) : illustrations |
